PREX2 contributes to radiation resistance by inhibiting radiotherapy-induced tumor immunogenicity via cGAS/STING/IFNs pathway in colorectal cancer
Authors:
Open Access
- 12 April 2024
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-20
Abstract
Background: Colorectal cancer (CRC) lacks established biomarkers or molecular targets for predicting or enhancing radiation response. Phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 2 (PREX2) exhibits intricate implications in tumorigenesis and progression. Nevertheless, the precise role and underlying mechanisms of PREX2 in CRC radioresistance remain unclear. Methods: RNA-seq was employed to identify differentially expressed genes between radioresistant CRC cell lines and their parental counterparts. PREX2 expression was scrutinized using Western blotting, real-time PCR, and immunohistochemistry. The radioresistant role of PREX2 was assessed through in vitro colony formation assay, apoptosis assay, comet assay, and in vivo xenograft tumor models. The mechanism of PREX2 was elucidated using RNA-seq and Western blotting. Finally, a PREX2 small-molecule inhibitor, designated PREX-in1, was utilized to enhance the efficacy of ionizing radiation (IR) therapy in CRC mouse models. Results: PREX2 emerged as the most significantly upregulated gene in radioresistant CRC cells. It augmented the radioresistant capacity of CRC cells and demonstrated potential as a marker for predicting radioresistance efficacy. Mechanistically, PREX2 facilitated DNA repair by upregulating DNA-PKcs, suppressing radiation-induced immunogenic cell death, and impeding CD8+ T cell infiltration through the cGAS/STING/IFNs pathway. In vivo, the blockade of PREX2 heightened the efficacy of IR therapy. Conclusions: PREX2 assumes a pivotal role in CRC radiation resistance by inhibiting the cGAS/STING/IFNs pathway, presenting itself as a potential radioresistant biomarker and therapeutic target for effectively overcoming radioresistance in CRC.Keywords
Funding Information
- The National Key R&D Program of China (2021YFF1201004)
- the Guangzhou Basic and Applied Basic Research Topics (2023A04J2383)
- The National Natural Science Foundation of China (Grant No.82273358, 82003059, No.81872041)
This publication has 42 references indexed in Scilit:
- Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancerCancer Communications, 2023
- Radiation‐Induced Immunogenic Cell Death for Cancer RadioimmunotherapySmall Methods, 2023
- The Genome Sequence Archive Family: Toward Explosive Data Growth and Diverse Data TypesGenomics, Proteomics & Bioinformatics, 2021
- Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-AnalysisThe Oncologist, 2021
- EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data2020
- Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated With Adjuvant Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage ResponseMolecular Cell, 2017
- DNA Double-Strand Break Repair Inhibitors as Cancer TherapeuticsChemistry & Biology, 2015
- P‐REX2, a novel PI‐3‐kinase sensitive Rac exchange factorFEBS Letters, 2004
- Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experienceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999